英特集團(000411.SZ):達成和解 億騰中國同意向英特藥業支付補償款2850萬元
格隆匯11月4日丨英特集團(000411.SZ)披露子公司與億騰中國合同糾紛案的進展,近日,億騰中國與英特藥業就雙方藥品經銷合同糾紛達成了和解,億騰中國同意向英特藥業支付補償款2850萬元,雙方各自向提起訴訟的法院申請撤回起訴,並同時申請解封被法院凍結的所有銀行賬户,督促法院及時解除各項保全措施。
2019年11月4日,根據杭州市中級人民法院協助執行通知書,億騰中國被凍結的銀行賬户中的2000萬元資金已被扣劃至法院執行賬户(後續英特藥業將申請該資金劃至英特藥業銀行賬户)。此外,2850萬元補償款中的餘款850萬元也已由億騰中國支付給英特藥業。目前,英特藥業與億騰中國均各自向相關法院提起了撤回起訴和解除財產保全的申請,相關手續正在辦理過程中。
如果和解事項全部履行完畢,英特藥業和億騰中國及其關聯方將不可撤銷且無條件地放棄向對方主張所有未決事項和潛在爭議的權利。截至公告日,公司沒有其他應予披露而尚未披露的重大訴訟、仲裁事項。
截至公告日,公司沒有其他應予披露而尚未披露的重大訴訟、仲裁事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.